Saad Usmani, MD, MBA, FACP, FASCO, explores treatment duration, patient characteristics, and toxicity profiles in transplant-ineligible patients with newly diagnosed multiple myeloma.
Saad Z. Usmani, MD, MBA, FACP, FASCO
Advertisement
Articles by Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible patients with newly diagnosed multiple myeloma from the CEPHEUS trial.
Advertisement
Latest Updated Articles
ASCO 2025: Fixed-Duration Treatment Emerges as Future of Multiple Myeloma ManagementPublished: June 4th 2025 | Updated:
ASCO 2025: Quadruplet Therapy Shows Promise in Transplant-Ineligible Multiple MyelomaPublished: June 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups
3
Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles
4
FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors
5
